

**Table DS1 Clinical characteristics of the eight individuals with 22q11.2DS-Schizophrenia and seizures while on clozapine.**

Seizures before clozapine	Seizures on clozapine	Clozapine dose at seizure (mg)	Myoclonus	Electroencephalography findings	
				Interictal epileptiform activity	Background
GTCS	GTCS (n=3), CPS (n=1), MS (n=1)	N/A	Yes	Left temporal, generalized	Dysrhythmia grade IV, mild generalized disturbance
GTCS	GTCS (n=1)	125	No	Left parasagittal, temporal and right hemisphere spread	Normal
GTCS, FMS	GTCS (n=5)	300-425	Yes	None	Normal
-	GTCS (n>4)	100-400	Yes	Generalized	6-7Hz mild slowing
-	GTCS (n=2)	250, <325	Yes	Generalized	2-6 Hz polymorphic high amplitude mixed frequency slow wave activity, bi-hemispheric, severe slowing
-	GTCS (n=2)	300, 400	Yes	None	Generalized slowing
-	GTCS (n=2)	350	No	No EEG	No EEG
-	GTCS (n=1), MS	275	Yes	Generalized	Normal, generalized low amplitude 15-25 Hz

FMS, focal motor seizure; GTCS, generalized tonic-clonic seizures; IPGE, idiopathic primary generalized epilepsy; MS, myoclonic seizures; N/A, not available; CPS, complex partial seizures.

**Table DS2 Clozapine treatment-emergent adverse effects affecting <25% of patients with 22q11.2DS-associated schizophrenia (22q11.2DS-Schizophrenia) and idiopathic schizophrenia (Idiopathic-Schizophrenia).**

Adverse effects	22q11.2DS-Schizophrenia (n=20)		Idiopathic-Schizophrenia (n=20)		Novartis clinical trials <sup>22</sup>
	N	%	N	%	%
<b>Central nervous system</b>					
Bradykinesia	4 <sup>a,b</sup>	20	0	0	NR
Fainting or drop attack	3	15	1	5	6
Dysphagia	3 <sup>b</sup>	15	0	0	NR
Headache	3	15	0	0	7
Freezing gait	2 <sup>b</sup>	10	0	0	NR
Restlessness	1	5	1	5	4
Concentration problems	1	5	2	10	NR
Weakness	1	5	1	5	1
<b>Cardiovascular</b>					
Hypertension	2	10	1	5	4
Hypotension	2	10	0	0	9
Chest pain/tightness	1	5	3	15	1
<b>Metabolic disturbances</b>					
Type 2 diabetes mellitus	2	10	3	15	3 <sup>c</sup>
Hypercholesterolemia	1	5	2	10	NR
Hyperlipidemia	0	0	1	5	NR
<b>Gastrointestinal and urogenital</b>					
Constipation	3	15	4	20	14
Urinary incontinence	3 <sup>b</sup>	15	1	5	1
Nausea	3	15	1	5	5
Vomiting	3	15	1	5	3
Urinary frequency	1	5	0	0	1
Bowel incontinence	1 <sup>b</sup>	5	0	0	NR
Heartburn	0	0	1	5	<4
Liver test abnormality	0	0	1	5	1
<b>Other</b>					
Yellow zone neutropenia <sup>d</sup>	4	20	3	15	<3 <sup>e</sup>
Falls	1	5	2	10	NR
Facial edema	1	5	0	0	NR
Dyspnea	1	5	1	5	1
Itchy feeling	0	0	1	5	NR

NR, not reported

<sup>a</sup>Includes one patient with pre-existing bradykinesia that worsened while on clozapine

<sup>b</sup>Includes one patient diagnosed with Parkinson's disease during the clozapine trial

<sup>c</sup>InterCePT study<sup>24</sup>

<sup>d</sup>White blood count (WBC)= $2.0-3.5 \times 10^9/L$  or absolute neutrophil count (ANC)= $1.5-2.0 \times 10^9/L$  or if a significant decline occurs in either count over a four week period e.g. a WBC decrease $\geq 3.0 \times 10^9/L$  or ANC decrease $\geq 1.5 \times 10^9/L$  <sup>e</sup>Includes leukopenia/decreased white blood cells/neutropenia